Scancell, the Nottingham based cancer vaccine developer, announced that the company is due to receive £2.85 million on 16th November 2011.
The receipt will trigger advisory fees along with bonus payments to directors of about £450,000. The board expects the net proceeds of circa £2.2 million will enable the company to complete the Phase I and Phase II clinical trials of SCIB1.
The SCLP share price has decreased by 36% over the last year.
Scancell Holdings Plc is currently graded c by LCF Research. To learn more, follow the link.
